Previous 10 | Next 10 |
2023-10-03 04:47:57 ET Summary Nuvation Bio is developing BET inhibitors for solid tumors, with lead asset NUV-868 in phase 1/1b trials. BET proteins play a role in gene regulation and chromatin remodeling, and inhibiting them may be therapeutic for cancer. NUV-868 is highly s...
2023-08-24 02:48:55 ET Summary Abrams' 13F portfolio value increased from $3.16B to $3.48B this quarter. The number of holdings in the portfolio increased from 15 to 16. The top three stakes in the portfolio make up approximately 45% of the total. This article is par...
2023-08-03 17:57:20 ET Nuvation Bio press release ( NYSE: NUVB ): Q2 GAAP EPS of -$0.09 beats by $0.02 . As of June 30, 2023, Nuvation Bio had cash, cash equivalents and marketable securities of $630.9 million. For further details see: Nuvation Bio GAAP EPS o...
Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Announced formati...
Scientific Advisory Board members bring significant global expertise in oncology drug and clinical development Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates,...
2023-05-25 01:43:01 ET Summary David Abrams’ 13F portfolio value increased this quarter from $2.80B to $3.16B. The number of positions remained steady at 15. Cantaloupe stake was increased while decreasing Teva Pharmaceutical. The top three positions are Lithia Motors, ...
2023-05-04 17:53:35 ET Nuvation Bio press release ( NYSE: NUVB ): Q1 GAAP EPS of -$0.10. Strong balance sheet with cash, cash equivalents and marketable securities of $646.6 million as of March 31, 2023 For further details see: Nuvation Bio GAAP EPS of -$0.10
Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Strong balance sh...
2023-03-15 17:09:08 ET Nuvation Bio press release ( NYSE: NUVB ): Q4 GAAP EPS of -$0.10 beats by $0.02 . As of December 31, 2022, Nuvation Bio had cash, cash equivalents and marketable securities of $661.0 million. For further details see: Nuvation Bio GAAP E...
Initiated both dosing regimens of the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Dosing ongoing for Phase 1 monotherapy study of NUV-868 Nominated undisclosed Drug-Drug Conjugate (DDC) as first clinical candidate; expect to submit an IND by year end 202...
News, Short Squeeze, Breakout and More Instantly...
Nuvation Bio Inc. Class A Company Name:
NUVB Stock Symbol:
NYSE Market:
Nuvation Bio Inc. Class A Website:
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at t...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nu...
Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at...